Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB-Derived NK Cells with Elotuzumab and ASCT for Multiple Myeloma
NCT01729091Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2013
- Primary completion
- Jun 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of umbilical cord blood-derived NK cells in multiple myeloma (MM), plasma cell leukemia (PCL), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2013; status: completed.
02
Drugs
umbilical cord blood-derived NK cells
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT01729091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01729091.